Impact of Tumor-shrinking Decoction (TSD) and Its Disassembled Prescriptions in Blood Serum on Gene Expression in Uterine Fibroid Cells

摘要

Objective: To study the differences in vitro gene expression of uterine fibroid cells under the effect of Tumor-shrinking Decoction (TSD) and its disassembled prescriptions in blood serum, so as to investigate the target genes of TSD in uterine fibroids. Methods: TSD and its disassembled prescriptions containing blood serums were prepared. BiostarH140s microarray was used to compare the differences in gene expression of uterine fibroid cells before and after 5-day medication of TSD and its disassembled prescriptions. The calculation was based on the ratios of signal intensity of those samples, and the up and down-regulated genes were screened. Result: TSD and its disassembled prescriptions containing blood serum obviously changed the genes expression of uterine fibroid cells. There were 17 down-regulated genes and 20 up-regulated genes in tonifyingqi group (TSD-a), 26 down-regulated genes and 41 up-regulated genes in softening hardness and dissipate binds group (TSD-b), 40 down-regulated genes and 46 up-regulated genes in resolving blood stasis group (TSD-c), as well as 15 down-regulated genes and 44 up-regulated genes in TSD group. Conclusion: It is concluded that the treatment with TSD and its disassembled prescriptions can induce a variety of gene expression in uterine fibroid cells. Various genes such as p62, Mnk2, Os9, PSAP, EEF2, DCN, REL, ADAMTS1, DKK1, KLF6 and OP18 played an important role in the process. The differences in genes expression are mainly associated with the cellular signal transduction and transcription, the cell cycle, and the genes encoding protein kinase activity.